share_log

Tharimmune | 8-K: Current report

SEC announcement ·  Feb 9 05:09
Summary by Futu AI
Tharimmune, Inc., a biopharmaceutical company incorporated in Delaware and listed on the Nasdaq Stock Market under the trading symbol THAR, has filed a Form 8-K current report with the United States Securities and Exchange Commission (SEC) on February 8, 2024. The report confirms that as of the same date, Tharimmune had a total of 11,739,676 shares of common stock issued and outstanding. The company, which is classified as an emerging growth company, has not changed its name or address since the last report. The filing was made in accordance with the requirements of the Securities Exchange Act of 1934 and was signed by an authorized representative of Tharimmune, Inc.
Tharimmune, Inc., a biopharmaceutical company incorporated in Delaware and listed on the Nasdaq Stock Market under the trading symbol THAR, has filed a Form 8-K current report with the United States Securities and Exchange Commission (SEC) on February 8, 2024. The report confirms that as of the same date, Tharimmune had a total of 11,739,676 shares of common stock issued and outstanding. The company, which is classified as an emerging growth company, has not changed its name or address since the last report. The filing was made in accordance with the requirements of the Securities Exchange Act of 1934 and was signed by an authorized representative of Tharimmune, Inc.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.